Related Experiment Video
Updated: May 8, 2026

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
Published on: November 23, 2013
Paraneoplastic cerebellar degeneration associated with an onconeural antibody against creatine kinase, brain-type
Syuichi Tetsuka1, Kaoru Tominaga, Eriko Ohta
1Division of Neurology, Department of Internal Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498 Japan; Department of Biochemistry, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498 Japan.
Abstract:
Onconeural immunity, a cancer-stimulated immune reaction that cross-reacts with neural tissues, is considered to be the principal pathological mechanism for paraneoplastic neurological syndromes (PNS). A common PNS is paraneoplastic cerebellar degeneration (PCD). We had encountered a PCD patient with urothelial carcinomas (UC) of the urinary bladder who was negative for the well-characterized PNS-related onconeural antibodies. In the present study, we aimed to identify a new PCD-related onconeural antibody, capable of recognizing both cerebellar neurons and cancer tissues from the patient, and applied a proteomic approach using mass spectrometry. We identified anti-creatine kinase, brain-type (CKB) antibody as a new autoantibody in the serum and cerebrospinal fluid from the patient. Immunohistochemistry indicated that anti-CKB antibody reacted with both cerebellar neurons and UC of the urinary bladder tissues. However, anti-CKB antibody was not detected in sera from over 30 donors, including bladder cancer patients without PCD, indicating that anti-CKB antibody is required for onset of PCD. We also detected anti-CKB antibody in sera from three other PCD patients. Our study demonstrated that anti-CKB antibody may be added to the list of PCD-related autoantibodies and may be useful for diagnosis of PCD.
Insights
Researchers identified a new onconeural antibody, anti-creatine kinase, brain-type (CKB), in a patient with paraneoplastic cerebellar degeneration (PCD) and bladder cancer. This discovery may aid in diagnosing PCD, a rare neurological complication of cancer.
Area of Science:
- Neuroimmunology
- Oncology
- Proteomics
Background:
- Paraneoplastic neurological syndromes (PNS), like paraneoplastic cerebellar degeneration (PCD), arise from onconeural immunity, where anti-cancer immune responses mistakenly target neural tissues.
- Standard diagnostic markers for PNS, including specific onconeural antibodies, were absent in a patient with PCD and urothelial carcinoma (UC).
Observation:
- A proteomic approach using mass spectrometry was employed to identify novel autoantibodies in the patient's serum and cerebrospinal fluid.
- The study focused on identifying an antibody that cross-reacts with both cerebellar neurons and the patient's UC tissues.
Findings:
- A novel autoantibody, anti-creatine kinase, brain-type (CKB), was identified in the patient's serum and cerebrospinal fluid.
- Immunohistochemistry confirmed that anti-CKB antibody targets both cerebellar neurons and UC tissues.
- Anti-CKB antibody was detected in three additional PCD patients but not in healthy donors or bladder cancer patients without PCD, suggesting its specificity for PCD.
Implications:
- Anti-CKB antibody represents a new potential biomarker for diagnosing paraneoplastic cerebellar degeneration.
- The findings expand the repertoire of known onconeural antibodies associated with PNS, improving diagnostic capabilities.
- This research highlights the importance of exploring novel autoantibodies in challenging PNS cases, particularly those lacking established serological markers.
Related Concept Videos
Encephalitis l: Introduction
Cerebral Edema ll: Pathophysiology
Neural Regulation
Encephalitis ll: Pathophysiology
Hepatic Encephalopathy
Cytotoxic Edema: Pathophysiology

